Kiniksa Q4 revenue rises on ARCALYST sales

Kiniksa Pharmaceuticals International

24/02/2026 12:39

Corrects EPS in Key Details table to $0.17, from $0.19

Overview

Biopharmaceutical firm's Q4 revenue up, driven by ARCALYST sales growth

Net income for Q4 was $14.2 mln, reversing a loss from last year

Company expects 2026 ARCALYST revenue between $900 mln and $920 mln

Outlook

Kiniksa expects 2026 ARCALYST net product revenue of $900 mln to $920 mln

Company expects KPL-387 Phase 2 data in second half of 2026

Kiniksa plans to initiate KPL-1161 Phase 1 trial by end of 2026

Result Drivers

ARCALYST SALES GROWTH - Significant growth in ARCALYST sales due to its adoption as a preferred treatment for recurrent pericarditis, contributing to a 62% year-over-year increase

CASH RESERVES - Cash balance increased by $170.4 mln in 2025, supporting further investments in pipeline

CLINICAL PIPELINE - Initiation of KPL-387 Phase 2/3 program and planned Phase 1 trial for KPL-1161 to expand treatment options

Company press release: ID:nGNX3hxSm1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
$202.13 mln
Q4 EPS
$0.17
Q4 Net Income
$14.20 mln
Q4 Operating Expenses
$182.36 mln
Q4 Pretax Profit
$23.27 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International PLC is $56.50, about 19.2% above its February 23 closing price of $47.39

The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 24 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)